Significant Shareholders

As at 17 May 2021, shareholders holding more than 3% of the share capital of Tissue Regenix Group Plc are:

Name of Shareholder Number of Shares % of Voting Rights
Lombard Odier 991,026,519 14.09
IP Group (London) 960,837,567 13.66
Mr Richard Griffiths (UK) 711,250,000 10.11
Premier Miton Investments (London) 694,608,642 9.8
Harwood Capital (London)  487,500,000 6.93

Board of Directors

Name of Shareholder Number of Shares % of Voting Rights
Jonathan Glenn, Chair 40,600,000 0.58
David Cocke, Chief Financial Officer 2,821,000 0.04
Daniel Lee, Chief Executive Officer 2,068,750 0.03
Shervanthi Homer-Vanniasinkam,
Non-executive director
1,628,222 0.02

Shares not in public hands as at 17 May 2021 - 3,532,755,443 - 50.23%

Shares in issue as at 17 May 2021 - 7,033,077,499 ordinary shares of 0.1p each

The securities of Tissue Regenix Group plc are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.

Key Advisors

You may also be interested in